Skeletal muscle relaxant activity of different formulation of span 60 niosomes
DOI:
https://doi.org/10.30827/ars.v63i1.22264Keywords:
Niosomes; baclofen; diazepam; Swiss albino mice; skeletal muscle relaxantAbstract
Introduction: Spasticity is a disease of motor neurons that manifests as accelerated muscle tone and stiffness. The niosomes can be formulated with the aid of proper adjustment of process parameters to enhance baclofen entrapment and sustaining the drug release.
Method: The main purpose of this study is to compare different formulations of span 60 niosomes containing baclofen for skeletal muscle relaxant activity on mice (Swiss albino mice) by rota rod method.
Results: The particle size of formulated niosomes was in the range of 3.62±0.54-4.08±0.64 µm and these were smooth, circular fit and generally small multilamellar. Entrapment efficiency of optimized formulation was 88.44±0.28 %. The most extreme % cumulative drug release was 87.88±8.66% after 10 h. The formulation stored at 4±2 °C temperature shows better stability (96.65±0.45) contrasted with raised temperature. Swiss albino mice were utilized for in vivo study and displayed improved muscle relaxant action as far as no. of tumbles from rota rod apparatus (p value =0.001) are concerned.
Conclusions: Nonetheless, diazepam treated mice were observed to have higher muscle relaxation than any dose of formulation tested. The formulation F9 shows better skeletal muscle relaxant activity as compared to F6, F7, F8 and F10 on mice (Swiss albino mice) by the rota rod technique.
Downloads
References
Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, Kuotsu K. Niosome: A future of targeted drug delivery systems.J Adv Pharm Technol Res. 2010; 1(4): 374–380. DOI: 10.4103/0110-5558.76435
Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech. 2009;10:1186–1192. DOI: 10.1208/s12249-009-9325-z
Xuemei Ge et al., Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics. 2019; 11(2): 55. DOI: 10.3390/pharmaceutics11020055
Sheena IP, Singh UV, Kamath R, Uma DP, Udupa N. Niosomalwithaferin A, with better tumor efficiency. Indian J Pharm Sci. 1998;60:45-48.
Fang JY, Hong CT, Chiu W T, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J of Pharm 2001; 219:61–72. DOI: 10.1016/s0378-5173(01)00627-5
Udupa N, Chandraprakash KS, Umadevi P, Pillai GK. Formulation and evaluation of methotrexate niosomes. Drug Dev Ind Pharm.1993; 19:1331–42.
Parthasarathi G, Udupa N, Umadevi P, Pillai G K. Niosome-encapsulated vincristine sulfate: improved anticancer activity with reduced toxicity in mice. J. Drug Targ. 1994; 2:173–82. DOI: 10.3109/10611869409015907
Uchegbu I F, Double J A, Turton J A, Florence A T. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharma Res. 1995; 12:1019–24. DOI: 10.1023/a:1016210515134
Williams D M, Carter K C, Baillie A J. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five nonionic surfactant vesicle preparations of sodium stibogluconate. J Drug Targ. 1995; 3:1–7. DOI: 10.3109/10611869509015926
Blazek-Welsh AI, Rhodes DG. Maltodextrin-based proniosomes. AAPS pharm Sci. 2001; 3:E1. DOI: 10.1208/ps030101
Arunothayanun P, Turton JA, Uchegbu IF, Florence AT. Preparation and in vitro in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical tubular niosomes. J Pharm Sci. 1999;88:34-38. DOI: 10.1021/js980286u
Uchegbu IF, Double JA, Turton JA, Florence AT. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm Res. 1995; 12:1019. DOI: 10.1023/a:1016210515134
Yoshioka T, Sternberg B, Florence AT. Preparation and Properties of Vesicles (Niosomes) Of Sorbitan Monoesters (Span-20, Span-40, Span-60 and Span-80) and A Sorbitan Triester (Span-85). Int J Pharm. 1994; 105:1-6.DOI: 10.1016/0378-5173(94)90228-3
Fang J Y, Yu S Y, Wu P C, Huang Y B, Tsai Y H. In vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm, 2001; 215:91–99. DOI: 10.1016/s0378-5173(00)00669-4
Manconi M, Sinico C, Valenti D, Loy G, Fadda A M. Niosomes as carriers for tretinoin. I. preparation and properties. Int J Pharm. 2002; 234:237–248. DOI: 10.1016/s0378-5173(01)00971-1
Manconi M, Valenti D, Sinico C, Lai F, Loy G, Fadda A M. Niosomes as carriers for tretinoin II. Influence of vesicular incorporation on tretinoin photostability. Int J Pharm. 2003; 260:261–272. DOI: 10.1016/s0378-5173(03)00268-0
Haselkorn JK, Little JW, et al. Spasticity Management in Multiple Sclerosis: Evidence-Based Management Strategies for Spasticity Treatment in Multiple Sclerosis. J Spinal Cord Med. 2005; 28(2). PMID: 15889701
Burchiel KJ, Hsu FP. Pain and spasticity after spinal cord injury: mechanisms and treatment. Spine. 2001; 26(24Suppl):S146–S160. DOI: 10.1097/00007632-200112151-00024
Brogden RN, Speight TM, Avery GS. Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs. 1974; 8(1):1–14. DOI: 10.2165/00003495-197408010-00001
Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol. 1985;17(2):107–116. DOI: 10.1002/ana.410170202
Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53(3):435–452. DOI: 10.2165/00003495-199753030-00007
Nance PW. Tizanidine: An α2-agonist imidazoline with antispasticity effects. Today’s Ther Trends. 1997;15(1):11–25.
Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs. 2000;59(3):487–495. DOI: 10.2165/00003495-200059030-00006
Cook JB, Nathan PW. On the site of action of diazepam in spasticity in man. J Neurol Sci. 1967; 5(1): 33–37. DOI: 10.1016/0022-510x(67)90005-6
Davidoff RA. Pharmacology of spasticity. Neurology 1978;28(9 Pt 2):46–51. DOI: 10.1212/wnl.28.9_part_2.46
Arunothayanun P, Turton JA, Uchegbu IF, Florence AT. Preparation and in vitro and in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical tubular niosomes. J Pharm Sci.1999; 88: 34-38. DOI: 10.1021/js980286u
Baillie AJ, Coombs GH, Dolan TF. Non-ionic surfactant vesicles (Niosomes) as delivery system for the anti- leishmanial drug, sodium stribogluconate. J Pharm Pharmacol. 1986; 38: 502-505. DOI: 10.1111/j.2042-7158.1986.tb04623.x
Varsheny HM, Tanwar YS, lowalekar R, Rathore KS. Designing and characterization of verapamil hydrochloride niosomes, Indian Pharmacy. 2007; 6:77-79.
Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharmac. 290 (1-2) (2005) 155-159. DOI: 10.1016/j.ijpharm.2004.10.026
Karki R, Mamatha GC, Subramanya G, Udupa N. Preparation, characterization and tissue diposition of niosomes containing isoniazide, Riv Jew Cent. 2008; 1(2):224-227.
Doijad RC, Manvi FV, Swathi S, Rony M. Niosomal drug delivery of cisplatin: development and characterization, Indian Drugs. 2008; 45(9):713-718.
Vogel HG. Drug Discovery and Evaluation, Pharmacological Assays, Second Edition, Springer-Verlag Berlin Heidelberg, New York, 2002; 398.
Keservani RK, Sharma AK, Suman R. Novel vesicular approach for topical delivery of baclofen via niosomes. Lat Am J Pharm 2010; 29 (8): 1364-1370.
Kamboj S, Saini V, Bala S. Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement. Scientific World Journal. 2014 2;2014:959741. doi: 10.1155/2014/959741.
Abdelkader H, Ismail S, Kamal A, Alany RG. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: Physicochemical characterization. Pharmazie. 2010, 65, 811–817.
Kaur IP, Mitra AK, Aggarwal D. Development of a vesicular system for effective ocular delivery of acetazolamide a comprehensive approach and successful venture. J Drug Deliv Sci Technol. 2007, 17, 33–41
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
